Results 131 to 140 of about 41,743 (197)

S1‐Leitlinie Diagnostik und Therapie der Necrobiosis lipoidica

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 3, Page 429-437, March 2026.
Zusammenfassung Die Necrobiosis lipoidica (NL) ist eine seltene granulomatöse Hauterkrankung unklarer Ätiologie, die gehäuft assoziiert mit Diabetes mellitus und anderen Komorbiditäten auftreten kann. Prädilektionsstellen sind die Unterschenkel, und hier insbesondere die prätibialen Bereiche. Die exakte Pathogenese ist weiterhin unklar.
Cornelia Erfurt‐Berge, Regina Renner, Melanie Peckruhn, Jörg Tittelbach, Dorothea Terhorst‐Molawi, Friederike Kauer, Joachim Dissemond   +6 more
wiley   +1 more source

Population pharmacokinetics of tofacitinib in patients with active ankylosing spondylitis. [PDF]

Int J Clin Pharmacol Ther
Tsuchiwata S, Suzuki A, Wang Q, Kanik K, Fallon L, Menon S.   +5 more
europepmc   +1 more source

NLRP12 Deficiency Enhances Tofacitinib Efficacy in DSS Colitis Via STAT1-M1 Polarization. [PDF]

Inflammation
Yi Y, Wei Q, Chen S, Li L, Dekyi W, Jia H, Shu X, Zhao Q, Chang Y.   +8 more
europepmc   +1 more source

Tofacitinib-Induced Weight Gain in Context: comment on the article by Wollenhaupt et al. [PDF]

ACR Open Rheumatol
Palmowski A, Buttgereit F, Simon D, Kleyer A, Drzeniek NM.   +4 more
europepmc   +1 more source

Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team. [PDF]

Intest Res
Hong SM, Kim DH, Bae JH, Shin SY, Song EM, Kim JE, Yang YJ, Yoon J, Kang SB, Kim ES, Kim SE, Kim SJ, Lee J, Na SY, Park SJ, Park SH, Choi M, Kim MH, Moon W, Jung SA.   +19 more
europepmc   +1 more source

From apremilast to JAK inhibitors-salvage treatment strategies for refractory palmoplantar pustulosis: case series. [PDF]

Front Med (Lausanne)
Pan Y, Jin D, Meng F, Zhang H, Tang J, Guo C, Li C, Ma J.   +7 more
europepmc   +1 more source

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis. [PDF]

Rheumatol Ther
Takeuchi T, Tanaka Y, Yamanaka H, Yamaoka K, Sugiyama N, Iikuni N, Toyoizumi S, Kwok K, Tsai WC, Mysler E, Moots RJ, Smolen JS, Fleischmann R.   +12 more
europepmc   +1 more source

Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis. [PDF]

Front Pharmacol
Wu H, Zhou Y, Chen X, Wang L, Guo Y, Du X, Miao X.   +6 more
europepmc   +1 more source

Multi-omics identification of immune-related biomarkers predicting tofacitinib response in rheumatoid arthritis. [PDF]

Front Immunol
Lu F, Shao Y, Chen Q, Liu Q, Liu H, Liu Z, Li Y.   +6 more
europepmc   +1 more source

Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis. [PDF]

Neurotherapeutics
Zhao R, Yan C, Zhong H, Huan X, Jin L, He D, Xi J, Li Y, Xiao B, Luo F, Zhao C, Song J, Luo S.   +12 more
europepmc   +1 more source